FGFR agonists

Details for Australian Patent Application No. 2003205716 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

Inventors Ullrich, Axel; Bange, Johannes

Agent Davies Collison Cave

Pub. Number AU-B-2003205716

PCT Number PCT/EP03/00953

PCT Pub. Number WO2003/063893

Priority 60/353,831 31.01.02 US; 02 002 358.6 31.01.02 EP

Filing date 30 January 2003

Wipo publication date 2 September 2003

Acceptance publication date 21 August 2008

International Classifications

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 5/14 (2006.01) Drugs for disorders of the endocrine system

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

A61P 15/00 (2006.01) Drugs for genital or sexual disorders

A61P 19/00 (2006.01) Drugs for skeletal disorders

A61P 19/08 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 5/20 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - one of the fusion partners being a B lymphocyte

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12Q 1/02 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving viable micro-organisms

G01N 33/15 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Medicinal preparations

Event Publications

17 July 2003 Complete Application Filed

  Priority application(s): 60/353,831 31.01.02 US; 02 002 358.6 31.01.02 EP

18 September 2003 Application Open to Public Inspection

  Published as AU-B-2003205716

21 August 2008 Application Accepted

  Published as AU-B-2003205716

18 December 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003205717-NEW MEDICINAL COMPOSITIONS CONTAINING HETEROCYCLICAL COMPOUNDS IN ADDITION TO ANTICHOLINERGICS

2003205715-THERMAL AND/OR ACOUSTIC INSULATION SYSTEM AND INSULATION ELEMENT